Unilife Corp

Unilife — Investor Presentation (February 2010)

22 slides from Unilife's investor presentation, Feb 17, 2010

  1. Slide 1: An emerging global leader for innovative safety medical devices

    Slide 1: An emerging global leader for innovative safety medical devices

    An emerging global leader for innovative safety medical devices February 2010

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements

  3. Slide 3: Business Overview

    Slide 3: Business Overview

    Well positioned to succeed in fast-growing healthcare & pharmaceutical markets being driven to mandatory use First range of prefilled & clinical syringes with a technology platform of automatic, fully integrated safety features Sanofi-aventis (largest prefilled syringe purchaser) paying $40m for Uni

  4. Slide 4: The Global Transition to Safety Syringes

    Slide 4: The Global Transition to Safety Syringes

    The Global Transition to Safety Syringes 1.3m^ people die annually from unsafe injection practices Needlestick injuries a serious threat to healthcare workers US mandates and enforces safety syringes within facilities Europe and other international markets now following Pharmaceutical companies must

  5. Slide 5: Portfolio of Best-in-Class Safety Syringes

    Slide 5: Portfolio of Best-in-Class Safety Syringes

    Portfolio of Best-in-Class Safety Syringes Key proprietary features: Automatic needle retraction Operator controls speed of needle retraction from body into the barrel Auto-disable (anti-tampering) Fully integrated within barrel Virtually eliminates infection risk from needlestick injuries or aeroso

  6. Slide 6: Unilife Brand Architecture

    Slide 6: Unilife Brand Architecture

    Unilife Brand Architecture Ready-to-Fill (Prefilled) syringes (glass barrel) Supplied to pharmaceutical companies Clinical syringes (plastic barrel for use with vials) Supplied for use by healthcare workers and self-injecting patients (i.e. insulin)

  7. Slide 7: Key Target Markets

    Slide 7: Key Target Markets

    Key Target Markets Targeting fast-growing and non-crowded markets that are pre-conditioned to demand premium safety devices Unilife Target Market Volumes^ (billions) Annual Growth Rate Capacity For Premium Devices Market Transition to Safety Level of Comp. Pharmaceutical High 2.7 High High Mature Lo

  8. Slide 8: Pharmaceutical Market for Prefilled Syringes

    Slide 8: Pharmaceutical Market for Prefilled Syringes

    Pharmaceutical Market for Prefilled Syringes More than 2.7* billion prefilled syringes used globally $1.5** billion market growing at more than 15% annually 50+ injectable drugs and vaccines are now prefilled Market now restricted to attaching ancillary safety devices to standard prefilled syringes

  9. Slide 9: Agreements with sanofi-aventis

    Slide 9: Agreements with sanofi-aventis

    Agreements with sanofi-aventis Long-term relationship with 'top 5' pharmaceutical leader Exclusive Agreement signed in July 2008 €10m fee for exclusive right to negotiate Unifill(tm) purchase Agreed to start and fund the industrialization program Industrialization Agreement signed in June 2009 Commi

  10. Slide 10: The Unifill Syringe

    Slide 10: The Unifill Syringe

    The world's first true prefilled safety syringe Insertion into standard prefilled fill-finish systems Use of proven materials for components in fluid path All safety features fully integrated inside glass barrel Streamlines filling and packaging processes Compact in size for easy handling & convenie

  11. Slide 11: Unifill is the only primary syringe container with safety mechanism inside the glass barrel

    Slide 11: Unifill is the only primary syringe container with safety mechanism inside the glass barrel

    Unifill(tm) is the only primary syringe container with safety mechanism inside the glass barrel Competitive Position Unifill (tm) syringes Glass Prefilled Syringe Fully Integrated External Sheath Controlled Retraction into Barrel Active Activation Needle Guard Passive Activation Stand - - Alone Need

  12. Slide 12: Ancillary Safety Products Attached onto Standard Prefilled Syringes

    Slide 12: Ancillary Safety Products Attached onto Standard Prefilled Syringes

    Ancillary Safety Products Attached onto Standard Prefilled Syringes Unifill syringe Ancillary Safety Products Attached onto Standard Prefilled Syringes The Unifill(tm) Syringe Competitive Comparison

  13. Slide 13: Unifill Industrialization program

    Slide 13: Unifill Industrialization program

    Unifill(tm) Industrialization program Commenced in July 2008 Target completion late 2010 Mikron engaged for assembly Assembly process validated 60m / year assembly line ready late 2010 Further assembly lines to have 150m per year capacity

  14. Slide 14: Unitract Range of 1mL Syringes

    Slide 14: Unitract Range of 1mL Syringes

    Unitract(tm) Range of 1mL Syringes Target markets include Healthcare facilities Diabetes / home-injection Harm reduction Insulin, TB and Safe variants FDA and CE Mark certified* US production commenced * Certification applies to product manufactured in China. US certification pending

  15. Slide 15: Positioning Unilife for Success

    Slide 15: Positioning Unilife for Success

    ISO-13485 certified with FDA-registered facilities in PA Team of more than 120 world-class staff Strong patent position for our proprietary products Strong cash position, multiple funding / revenue streams Successfully redomiciled from Australia to the US NASDAQ listing supports ongoing expansion ac

  16. Slide 16: New Global Headquarters and Production Center

    Slide 16: New Global Headquarters and Production Center

    Positioning Unilife for Success New Global Headquarters and Production Center State-of-the-art facility to meet highest industry standards Stage one capacity supports 400 million syringes a year 2nd stage approval supports production of 1 billion units Ready for operations in late 2010

  17. Slide 17: Additional pharmaceutical relationships

    Slide 17: Additional pharmaceutical relationships

    Positioning Unilife for Success Additional pharmaceutical relationships

  18. Slide 18: Development of Pipeline Products

    Slide 18: Development of Pipeline Products

    Positioning Unilife for Success Glass ready-to-fill Unifill(tm) Select Attachable needles Plastic for vial Unitract Clinical Range 3 & 5mL with Luer needle Development of Pipeline Products

  19. Slide 19: Strong Product Pipeline

    Slide 19: Strong Product Pipeline

    Strong Product Pipeline Current 2010-2011 2012 + Unifill(tm) Select attachable needles^ Unitract(tm) 3 & 5mL with luer needle Unifill(tm) syringe with fixed needle Unitract(tm) 1mL Insulin, TB and Safe ^ subject to securing agreement with an interested pharmaceutical party

  20. Slide 20: Background Financial Data

    Slide 20: Background Financial Data

    Background Financial Data Selected Data Strong cash position $41.4m (as of 12/31/09) $14m from sanofi-aventis in 2008, regular milestone payments Raised approx $47.5m in US / Australian markets Nov. 2009 Secured $5.2m package from PA Government in Oct. 2009 Cap. Structure Approx 50m shares of common

  21. Slide 21: Upcoming Milestones

    Slide 21: Upcoming Milestones

    Upcoming Milestones Commercial release of US-made Unitract(tm) 1mL syringes Completion of negotiations for Unifill(tm) exclusivity list Listing on NASDAQ Open new global headquarters and production facility in PA Completion of Unifill(tm) industrialization program Agreements with additional pharmace

  22. Slide 22: Summary

    Slide 22: Summary

    Summary Unifill(tm) syringe represents 'disruptive technology' World's major prefilled buyer committed $40m^ (pre-sales) Industry certified with FDA-registered production facilities Strong cash position, multiple funding & revenue streams Well-positioned to attain strong market share in the pharmace

Source: SEC EDGAR · 8-K filed Feb 17, 2010

More decks from Unilife Corp